Table 2.

Incidence rates and hazard ratios of vancomycin compared to all comparators and vancomycin compared to singular comparator.

	N	Cases	Person timeb	Incidence rateb	95% CI	Crude HR	95% CI	Adjusted HRc	95% CI
Vancomycina	5449	22	22.35	0.93	0.94–1.92
Comparators	27,548	107	113.93	0.96	0.77–1.12	1.04	0.85–1.90	0.74	0.45–1.21
Cefazolin	20,124	58	83.31	0.69	0.53–0.89	1.40	0.86–2.29	1.01	0.55–1.83
Linezolid	251	6	1.03	5.76	2.59–12.83	0.17	0.07–0.42	0.17	0.01–0.46
Piperacillin	3885	25	16.00	1.54	1.04–2.28	0.63	0.35–1.11	0.47	0.24–0.91
Cefepime	433	2	1.79	1.11	0.28–4.43	0.87	0.45–3.70	0.80	0.19–3.69
Meropenem	379	7	1.58	4.44	2.12–9.32	0.22	0.09–0.51	0.21	0.10–0.52
Ertapenem	2205	8	9.13	0.86	0.43–1.73	1.11	0.51–2.50	0.47	0.19–1.17
Daptomycin	271	1	1.12	0.88	0.12–6.25	1.09	0.15–8.11	0.99	0.12–8.19

95% CI 95% confidence interval, HR hazard ratio.

^aIndex group.

^bPer 10 person-years.

^cAdjusted for age, gender, medical history, co-medication, type of surgery, main diagnosis (not Included in model because of low cell count: vancomycin vs. piperacillin ,vancomycin vs. ertapenem, vancomycin vs. daptomycin, and vancomycin vs. cefepime).